Dengue vaccine

Dengue Vaccine is a vaccine used to prevent Dengue fever, a mosquito-borne tropical disease caused by the dengue virus. Dengue fever is a significant cause of illness and death in the tropics and subtropics, with over 2.5 billion people at risk for the disease worldwide.

History[edit | edit source]

The development of a dengue vaccine has been a public health priority for many years. The first dengue vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur, was first licensed in 2015 and has been introduced in the national immunization programs of several countries.

Types of Dengue Vaccines[edit | edit source]

There are several types of dengue vaccines that are in various stages of development. These include:

Dengvaxia (CYD-TDV) by Sanofi Pasteur
TAK-003 by Takeda Pharmaceutical Company
TV003/TV005 by the U.S. National Institutes of Health
DENVax by Panacea Biotec

Efficacy and Safety[edit | edit source]

The efficacy and safety of dengue vaccines are still under study. The World Health Organization (WHO) recommends the use of the Dengvaxia vaccine in individuals aged 9-45 years living in areas where dengue is endemic and who have confirmed previous dengue virus infection.

Side Effects[edit | edit source]

Like all vaccines, dengue vaccines can cause side effects, although not everybody gets them. The most common side effects are mild and include pain at the injection site, headache, and mild fever.

Future Research[edit | edit source]

Future research on dengue vaccines focuses on improving the efficacy and safety of the vaccines, as well as developing vaccines that can provide protection against all four dengue virus serotypes.

References[edit | edit source]

Dengue vaccine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.